Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413913 | 1.00 | POLB (0.59) | POLBP2RY2P2RY4P2RY6L3MBTL1 | |
| SCHEMBL2580883 | 0.90 | POLB (0.59) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL8660989 | 0.90 | POLB (0.59) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL1962182 | 0.89 | POLB (0.64) | POLBP2RY2P2RY4P2RY6L3MBTL1 | |
| SCHEMBL16359952 | 0.89 | POLB (0.64) | POLBP2RY2P2RY4P2RY6L3MBTL1 | |
| SCHEMBL5414175 | 0.88 | POLB (0.46) | POLBP2RY2P2RY4P2RY6L3MBTL1 | |
| SCHEMBL7772982 | 0.88 | POLB (0.63) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL8664179 | 0.87 | POLB (0.57) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3933966 | 0.87 | POLB (0.57) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL28925328 | 0.87 | POLB (0.66) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032405-A4 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | WELLSTAT THERAPEUTICS CORP (US) | 2007-05-02 | — | — | EP | claimed |
| US-RE39573-E1 | Antimutagenic compositions for treatment and prevention of photodamage to skin | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-04-17 | — | — | US | claimed |
| US-6465440-B2 | ADMINISTERING TO SKIN A COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES IN CONCENTRATIONS SUFFICIENT TO ENHANCE DNA REPAIR OR REDUCE MUTATION FREQUENCY IN A VEHICLE CAPABLE OF DELIVERING DEOXYRIBONUCLEOSIDES TO SKIN CELLS | WELLSTAT THERAPEUTICS CORPORATION | 2002-10-15 | — | — | US | claimed |
| US-6417170-B2 | ADMINISTERING TO SKIN A COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES IN CONCENTRATIONS SUFFICIENT TO ENHANCE DNA REPAIR OR REDUCE MUTATION FREQUENCY IN A VEHICLE CAPABLE OF DELIVERING DEOXYRIBONUCLEOSIDES TO SKIN CELLS | PRO-NEURON, INC. | 2002-07-09 | — | — | US | claimed |
| US-20020006913-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010044421-A1 | Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells | PRO-NEURON, INC. | 2001-11-22 | — | — | US | claimed |
| US-20010044419-A1 | Antimutagenic compositions for treatment and prevention of photodamage to skin | PRO-NEURON, INC. | 2001-11-22 | — | — | US | claimed |
| EP-1032405-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999022741-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. (US) | 1999-05-14 | — | — | WO | claimed |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | POLB 46/4885P2RY2 1540/4885P2RY4 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.